Amgen’s Tavneos: When Approval No Longer Settles the Evidence
Examine how trial reliability, regulatory proceedings, and patient questions reshape the assessment of an acquired drug.
12 min readRead more
AFTER APPROVAL
Approval is one point in a longer story.
Follow the questions that arise when evidence is reconsidered: what remains reliable, what changes for patients, and who is accountable?
The seven-part series is currently available in Chinese. The English extended analysis below examines the Tavneos case and its wider questions.